Clover Health Forecasts First-Ever GAAP Net Income Profitability in 2026 Amidst 53% Medicare Advantage Membership Growth
CLOV sits 20% above its 52-week low of $2.12.
Summary
Clover Health announced a 53% increase in Medicare Advantage membership for 2026 and anticipates achieving its first-ever full-year GAAP Net Income profitability in 2026, driven by strategic growth and improved economics.
Key Events · Earnings and Guidance · CLOV
-
Forecasts First-Ever GAAP Net Income Profitability
Clover Health expects to achieve full-year GAAP Net Income profitability for the first time in 2026, indicating a significant financial milestone and improved operational efficiency.
-
Strong Medicare Advantage Membership Growth
The company reported a 53% year-over-year increase in Medicare Advantage (MA) membership during the Annual Election Period (AEP), reaching approximately 153,000 members as of January 1, 2026.
-
Improved Cohort Economics and Quality Ratings
Profitability is supported by strong returning member retention (>95%), a 4.0 Stars rating for its PPO plans for payment year 2026, favorable CMS rate updates, and continued SG&A leverage.
-
Industry-Leading Clinical Quality
Over 97% of Clover's MA membership is in its flagship PPO plan, which is ranked #1 nationally on core HEDIS quality measures for the second consecutive year.
Analysis · CLOV · Finance
Clover Health's announcement of expected full-year GAAP Net Income profitability for 2026 marks a critical turning point for the company, signaling a significant improvement in its financial trajectory. This positive outlook is underpinned by robust operational performance, including a substantial 53% year-over-year growth in Medicare Advantage membership. The company's strategic focus on core markets, strong member retention, and improved cohort economics, combined with a 4.0 Stars rating for its PPO plans and favorable CMS rate updates, suggests a sustainable path to profitability. This development could lead to a material re-evaluation of the company's investment thesis, shifting focus from growth at all costs to profitable expansion.
How filings like this one have moved
In the 30 days to Sep 16, 2026, 40.6% of the 409 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.50%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CLOV was trading at $2.54 on NASDAQ in the Finance sector, with a market capitalization of approximately $1.3B. The 52-week trading range was $2.12 to $4.87. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.